The Breakthroughs Powering Culture-Free Diagnostics.

SPLENDID™ isolates and characterizes pathogens directly from whole blood, providing results without needing blood culture.

The SPLENDID™ platform is built around the capability of capturing and characterizing rare cells directly from clinical specimens.

SPLENDID Platform benchtop phenotypic AST sepsis diagnostic test single cell

The Holy Grail of Diagnostics.

Capture 1-100 pathogens for every billion human cells in a standard 10 mL blood sample and provide clinically actionable results in minutes.

» BLASTID is transforming diagnostics

See what’s hiding in a 10 mL blood sample

PATHOGEN ENRICHMENT

Microfluidic Capture.

SPLENDID's pathogen enrichment technology for single-cell analysis was co-developed with researchers from the Paulsson Lab at Harvard Medical School.

Ultra-rapid capture of live pathogens from 5-10 mL of blood with >99.99% efficiency. The gentle process keeps all bacteria and fungal cells viable for downstream species-level ID and phenotypic AST.

Microfluidic capture of bacteria occurs in minutes via the SPLENDID™ Platform

LIVE IMAGING

Super-Resolution Microscopy.

Our label-free, single-cell optical identification system uses Differential Phase Microscopy (DPC) to classify and identify pathogens, enabling ultra-rapid and cost-effective detection even in polymicrobial infections.

SPECIES ID & AST

AI-Powered Image Analysis.

Trained on hundreds of thousands of pathogen images, SPLENDID™’s AI-powered image algorithms analyze real-time morphological changes and growth patterns to determine ID & AST profiles for personalized patient treatments.

The platform capitalizes on direct observation of live cells growing, dividing, and responding to antibiotics.

See antibiotic effects on susceptible E. coli (top) and uninhibited growth of S. aureus clusters (bottom) on chip.

Harness the breakthroughs of microfluidics, advanced microscopy, and AI for single-cell diagnostics.

Connect with our team.

Collaborate with BLASTID.

BLASTID is actively engaged with hospital systems, clinical laboratories, and key stakeholders to bring culture-free, direct-from-blood diagnostics into routine practice.

Join us on the journey to unlock massive patient impact and commercial success.